A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...
Austin Chiang, MD, MPH: One innovation that's happening in my specialty of gastroenterology is artificial intelligence. Ben ...
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...
Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...
The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...
The government-funded study was small and experts say it's not yet clear how safe these drugs are for people who don't need ...
Diabetes UK reported that more than 12 million people in the UK are now living with diabetes or prediabetes. The total ...
Backed by Ping An Group's "integrated finance + health and senior care" dual-engine strategy and its extensive resources in finance and technology, Ping An Health's AI healthcare development is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback